GlassScriptPhysician profile
Moayyed Moallem
NPI 1760445050
$6,603.53
in general payments reported to CMS, 2019-2025
39 companies · $2,425 in 2025
The $2,425 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $36.74 · 2021: $57.26 · 2022: $724 · 2023: $1,857 · 2024: $1,392 · 2025: $2,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,499 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,499.47 |
| Education | $175.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,114.37 | 2022-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,076.82 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Avadel Cns Pharmaceuticals, LLC | $364.73 | 2024-2025 | Lumryz |
| Mallinckrodt Hospital Products INC. | $329.60 | 2022-2025 | Acthar |
| Jazz Pharmaceuticals INC. | $309.76 | 2021-2025 | Xyrem, Xywav |
| Genzyme Corporation | $290.14 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.20 | 2022-2025 | Ofev, Stiolto Respimat, Jascayd |
| Regeneron Healthcare Solutions, INC. | $248.78 | 2022-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $244.54 | 2023-2025 | Uptravi, Opsumit |
| Grifols USA, LLC | $213.83 | 2022-2025 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $195.28 | 2023-2025 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $185.59 | 2023-2025 | Glassia |
| United Therapeutics Corporation | $168.62 | 2022-2025 | Tyvaso, Tyvaso |
| Philips North America LLC | $148.39 | 2022-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Inspire Medical Systems, INC. | $142.09 | 2025 | Inspire |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $139.27 | 2023-2025 | Sunosi |
| Ekos Corporation | $110.91 | 2019 | |
| Insmed, INC. | $100.92 | 2024-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $92.46 | 2022-2025 | Zerbaxa, Recarbrio, Dificid |
| E.R. Squibb & Sons, L.L.C. | $86.81 | 2021-2023 | Eliquis |
| Inogen, INC. | $78.27 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Sanofi-Aventis U.S. LLC | $67.99 | 2024 | |
| Novartis Pharmaceuticals Corporation | $61.04 | 2023-2024 | |
| Verona Pharma, INC. | $52.86 | 2025 | Ohtuvayre |
| Pfizer INC. | $51.52 | 2023-2025 | |
| Pharming Healthcare, INC. | $46.72 | 2023-2024 | Ruconest |
| Electromed, INC. | $44.57 | 2024-2025 | Smartvest |
| Resmed Corp | $40.07 | 2025 | |
| Ani Pharmaceuticals, INC. | $40.05 | 2025 | Purified Cortrophin Gel |
| Abbvie INC. | $38.78 | 2023 | |
| Baxter Healthcare | $38.19 | 2025 | Hillrom - Monarch Airway Clearance System |
| Mylan Specialty L.P. | $37.12 | 2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $37.08 | 2022-2023 | Xarelto |
| Amgen INC. | $32.55 | 2023-2025 | Tezspire |
| Pulmonx Corporation | $28.56 | 2023-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Azurity Pharmaceuticals, INC. | $17.51 | 2023 | Horizant |
| Viatris Specialty LLC | $14.12 | 2025 | Yupelri |
| Genentech USA, INC. | $13.89 | 2024 | Xolair |
| Teva Pharmaceuticals USA, INC. | $13.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moayyed Moallem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.